Chemotherapy with mitomycin C and capecitabine in patients with advanced colorectal cancer pretreated with irinotecan and oxaliplatin

Tumori

Volumn 92, Issue 4, 2006, Pages 285-289

  Rimassa, Lorenza ^a   Gullo, Giuseppe ^a   Carnaghi, Carlo ^a   Abbadessa, Giovanni ^a   Zuradelli, Monica ^a   Tronconi, Maria Chiara ^a   Pressiani, Tiziana ^a   Santoro, Armando ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Advanced colorectal cancer; Capecitabine; Mitomycin C

Indexed keywords

CAPECITABINE; IRINOTECAN; MITOMYCIN C; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ASTHENIA; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL ARTICLE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; REVIEW; TOXICITY TESTING;

EID: 33749533138     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160609200404     Document Type: Review

References (24)

1. Mayer RJ: Chemotherapy for metastatic colorectal cancer. Cancer, 70: 1414-1424, 1992.
2. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol, 16: 301-308, 1998.
3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, Gruia G, Award L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as firstline treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355: 1041-1047, 2000.
4. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller L: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med, 343: 905-914, 2000.
5. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18: 2938-2947, 2000.
6. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pilot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol, 22: 23-30, 2004.
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chan I, Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med, 351: 337-345, 2004.
8. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350: 2335-2342, 2004.
9. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, De Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 22: 229-237, 2004.
10. Schuller J, Cassidy J, Dumont E, Ross B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B: Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patinets. Cancer Chemother Pharmacol, 45: 291-297, 2000.
11. Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver G, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R: Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomised phase III study. J Clin Oncol, 19: 2282-2292, 2001.
12. Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Fring S, Jahn M, McKendick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Schmiegel WH, Seitz JF, Thompson P, Vieitez JM, Weitzel C, Harper P: Xeloda Colorectal Cancer Study Group. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol, 19: 4097-4106, 2001.
13. Borner MM, Schoffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Greim G, Peters GJ, van der Born K, Wanders J, de Boer RF, Martin C, Fumoleau P: Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. Eur J Cancer, 38: 349-358, 2002.
14. Bradner WT: Mitomycin C: a clinical update. Cancer Treat Rev, 27: 35-50, 2001.
15. Russello O, Romanini A, Civalleri D, Rosso R, Nicolin A, Sobrero A: Time-dependent interactions between 5fluorouracil and mitomycin C on a human colon cancer cell line, HCT-8, in vitro. Eur J Cancer Clin Oncol, 25: 571-572, 1989.
16. Ross P, Norman A, Cunningham D, Webb A, Iveson T, Padhani A, Prendiville J, Watson M, Massey A, Popescu R, Oates J: A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. Ann Oncol, 8: 995-1001, 1997.
17. Sawada N, Ishikawa T, Fukase Y, Nishida M, Yoshikubo T, Ishitsuka H: Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res, 4: 1013-1019, 1998.
18. Rao S, Cunningham D, Price T, Hill ME, Ross PJ, Tebbutt N, Norman AR, Oates J, Shellito P: Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. Br J Cancer, 91: 839-843, 2004.
19. Lim do H, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K: Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study. Cancer Chemother Pharmacol, 56: 10-14, 2005.
20. Chong G, Dickson JLB, Cunningham D, Norman AR, Rao S, Hill ME, Price TJ, Oates J, Tebbutt N: Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer, 93: 510-514, 2005.
21. Miller AB, Hoogstraaten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer, 47: 207-214, 1981.
22. Trotti A, Byhardt R, StetzJ, Gwede C, Corn B, Fu K, Gunderson L, McCormick B, Morrisintegral M, Rich T, Shipley W, Curran W: Common Toxicity criteria: version 2.0, an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys, 47: 13-47, 2000.
23. Hoff PM, Pazdur R, Lassere Y, Carter S, Samid D, Polito D, Abbruzzese JL: Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol, 22: 2078-2083, 2004.
24. Rosati G, Rossi A, Germano D, Reggiardo G, Manzione L: Raltitrexed and mitomycin-C as third-line chemotherapy for colorectal cancer after combination regimens including 5-fluorouracil, irinotecan and oxaliplatin: a phase II study. Anti-cancer Res, 23: 2981-2985, 2003.